Bayforest Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Bayforest Capital’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-171	Closed	-$41.6K	–	740
2025 Q1	$41.6K	Sell	171 -194	-53%	-$58.4K	0.02%	579
2024 Q4	$120K	Buy	+365	New	+$124K	0.15%	265

Other funds holding BIO

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FPA

First Pacific Advisors El Segundo, California $7.14B AUM 21.51% 1-Year Est. Return

Bayforest Capital's BIO Position: Q2 2025 in Review

Bayforest Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2025, closing a stake of 171 shares — an estimated $41.6K sold.

Bayforest Capital first reported a position in BIO in Q4 2024 and held it in 2 quarters. The position peaked at $120K in Q4 2024. 383 funds tracked by Wall St. Rank hold BIO as of Q2 2025.

Bayforest Capital reported no remaining Bio-Rad Laboratories Class A position as of Q2 2025 after selling out during the quarter.
Bayforest Capital sold 171 Bio-Rad Laboratories Class A shares in Q2 2025, an estimated $41.6K.
Bayforest Capital first reported a position in Bio-Rad Laboratories Class A in Q4 2024 and held it in 2 quarters.
Bayforest Capital's Bio-Rad Laboratories Class A position peaked at $120K in Q4 2024.
383 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2025.

Based on Bayforest Capital's 13F filing for Q2 2025, filed 28 Jul 2025.